Patents Assigned to Agensys, Inc.
  • Gene upregulated in cancers of the prostate
    Patent number: 7928212
    Abstract: The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: April 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Arthur B. Raitano, Rene S. Hubert, Steve Chappell Mitchell, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 162P1E6 useful in treatment and detection of cancer
    Patent number: 7923543
    Abstract: A novel gene (designated 162P1E6) and its encoded protein, and variants thereof, are described wherein 162P1E6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 162P1E6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 162P1E6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 162P1E6 can be used in active or passive immunization.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: April 12, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 158P3D2 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20110082095
    Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.
    Type: Application
    Filed: October 6, 2010
    Publication date: April 7, 2011
    Applicant: AGENSYS, INC.
    Inventors: ARTHUR B. RAITANO, AYA JAKOBOVITS, PIA M. CHALLITA-EID, STEVEN B. KANNER, WANGMAO GE, JUAN J. PEREZ-VILLAR, ROBERT KENDALL MORRISON
  • Secreted protein called 36P6D5 characteristic of tumors
    Patent number: 7897740
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary, and pancreas.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: March 1, 2011
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Aya Jakobovits, Mary Faris, Daniel E. H. Afar, Rene S. Hubert, Steve Chappell Mitchell
  • 121P1F1: a tissue specific protein highly expressed in various cancers
    Patent number: 7892548
    Abstract: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: February 22, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Rene S. Hubert, Steven Chappell Mitchell, Arthur B. Raitano, Mary Faris, Daniel E. H. Afar, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
    Patent number: 7884179
    Abstract: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: February 8, 2011
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Wangmao Ge, Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
    Patent number: 7879570
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: February 1, 2011
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20110020353
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: September 14, 2010
    Publication date: January 27, 2011
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-Chi Jia, Jean Gudas
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS
    Publication number: 20100330107
    Abstract: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 5, 2010
    Publication date: December 30, 2010
    Applicants: AGENSYS, INC., SEATTLE GENETICS
    Inventors: Jean Gudas, Aya Jakobovits, Zili An, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Dennis Benjamin, Ruth Moser, Peter Senter
  • Antibodies to protein expressed in prostate cancer
    Patent number: 7858760
    Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: December 28, 2010
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran
  • Antibodies to tumor associated proteins
    Patent number: 7858750
    Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: December 28, 2010
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
  • Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
    Patent number: 7842458
    Abstract: A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: November 30, 2010
    Assignee: Agensys, Inc.
    Inventors: Steven B. Kanner, Aya Jakobovits, Pia M. Challita-Eid, Wangmao Ge, Arthur B. Raitano
  • NUCLEIC ACIDS AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20100297005
    Abstract: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.
    Type: Application
    Filed: June 22, 2010
    Publication date: November 25, 2010
    Applicant: Agensys, Inc.
    Inventors: Arthur B. RAITANO, Pia M. Challita-Eid, Aya Jakobovits, Mary Faris, Wangmao Ge
  • NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20100297669
    Abstract: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.
    Type: Application
    Filed: June 22, 2010
    Publication date: November 25, 2010
    Applicant: Agensys, Inc.
    Inventors: Arthur B. RAITANO, Pia M. Challita-Eid, Aya Jakobovits, Mary Faris, Wangmao Ge
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20100297650
    Abstract: A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.
    Type: Application
    Filed: April 20, 2010
    Publication date: November 25, 2010
    Applicant: AGENSYS, INC.
    Inventors: ARTHUR B. RAITANO, PIA M. CHALLITA-EID, MARY FARIS, RENE S. HUBERT, WANGMAO GE, AYA JAKOBOVITS
  • NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20100297006
    Abstract: A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.
    Type: Application
    Filed: June 22, 2010
    Publication date: November 25, 2010
    Applicant: Agensys, Inc.
    Inventors: Arthur B. RAITANO, Pia M. Challita-Eid, Aya Jakobovits, Mary Faris, Wangmao Ge
  • NUCLEIC ACID ENCODING 238P1B2 USEFUL IN DETECTING CANCER
    Publication number: 20100291094
    Abstract: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.
    Type: Application
    Filed: May 21, 2010
    Publication date: November 18, 2010
    Applicant: AGENSYS, INC.
    Inventors: ARTHUR B. RAITANO, PIA M. CHALLITA-EID, MARY FARIS, RENE S. HUBERT, ROBERT KENDALL MORRISON, WANGMAO GE, AYA JAKOBOVITS
  • PROTEIN SHOWING ENHANCED EXPRESSION IN CANCER CELLS
    Publication number: 20100291126
    Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
    Type: Application
    Filed: July 23, 2010
    Publication date: November 18, 2010
    Applicant: AGENSYS, INC.
    Inventors: AYA JAKOBOVITS, MARY FARIS, ARTHUR B. RAITANO, ROBERT KENDALL MORRISON, DOUGLAS SAFFRAN, WANGMAO GE, PIA M. CHALLITA-EID
  • 125P5C8: tissue specific protein highly expressed in various cancers
    Patent number: 7834156
    Abstract: A novel gene (designated 125P5C8) and its encoded protein are described. While 125P5C8 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, bladder, kidney and colon cancers. Consequently, 125P5C8 provides a diagnostic and/or therapeutic target for cancers, and the 125P5C8 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: November 16, 2010
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Steve Chappell Mitchell, Daniel E. H. Afar, Arthur B. Raitano, Aya Jakobovits
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20100266498
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Application
    Filed: June 21, 2010
    Publication date: October 21, 2010
    Applicant: Agensys, Inc.
    Inventors: Mary FARIS, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits